Top 5 Clinical Trial Partnering in Asia Pacific Questions Answered

Partnerships in Clinical Trials Asia Pacific provides the answers to your most pressing partnering and outsourcing questions so your trial can benefit from the tremendous opportunities presented by outsourcing to Asia.

This December get your top 5 questions Answered at Partnerships in Clinical Trials Asia Pacific and walk away with the tools you need to overcome the unique operational, regulatory and ethical challenges in each region.

1. How can I leverage the advantages and disadvantages of local CROs versus global CROs?

Asia is highly regarded as a preferred location for global clinical trials, providing cost savings and a broad spectrum of available patient pools. Now, as outsourcing strategies mature, the focus is turning to finding the right partner mix and the most competitive sponsors are focusing on leveraging the right partner for the right trial in the right region. Experienced outsourcing experts from Astrazeneca Singapore, Bristol-Meyers Squibb Japan, and Boehringer Ingelheim USA will share proven strategies on how to select global and regional partners in the Asia-Pacific region.

2. How can I avoid common pitfalls and set up clinical trials efficiently and effectively in a new region?

From choosing the right partner for your trials to accelerating patient recruitment and retention to assuring project excellence through quality staffing and improved communication strategies, global executives from GSK Biologics, Amgen, Wyeth, Glenmark Pharmaceuticals and Wockhart will address these challenges to help you successfully run your clinical trials in the Asia Pacific region.

3. What can I do to minimize delays and truly expedite clinical trials when outsourcing to the Asia Pacific?

Every session at Partnerships in Clinical Trials Asia Pacific delivers industry insights from Pharma's most experienced outsourcing professionals including Merck Sereno, Genzyme, Genentech and Biogen IDEC. In addition you will gain access to the leading regional and global CROs all in one place so you can see who is truly getting the work done and delivering results.

4. How do I work with our partners to ensure quality and minimize safety concerns?

In order to define and manage quality in clinical trials in Asia Pacific it is important to ensure quality is taking place at all levels, plan for post-marketing requirements on the future of drug developments partnerships and work with sites and partners to ensure patient safety. Hear from sponsor companies from China along with the Safety and Pharmacovigilance team from the NIAD, NIH, DHH. Also make sure to sign up for the full day pharmacovigilance and product safety seminar.

5. What are the regional IP laws and regulatory nuances that I must be aware of to ensure that our company’s intellectual property is protected and our trials are regionally compliant?

With the rapid increase in clinical trials globally, the regulatory differences of each country can have a tremendous impact on timing and quality of your trials. Key regulatory agencies from USA, EU, Japan and China will discuss the requirements and what each region is focusing on with respect to priorities.

So join the conference December 1st and hear from 30+ Speakers on these and
all the other critical issues clinical trial executives are facing when expanding
their trials into the Asia Pacific region.